CECAD Microsite

Selected Publications

  • Castiglione R, Alidousty C, Holz B, Wagener S, Baar T, Heydt C, Binot E, Zupp S, Kron A, Wolf J, Merkelbach-Bruse S, Reinhardt HC, Büttner R, Schultheis AM: Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Modern Pathology, 2018 Nov 20. doi: 10.1038/s41379-018-0182-8.
  • Jachimowicz RD, Beleggia F, Isensee J, Bhavana VB, Goergens J, Bustos MA, Doll MA, Shenoy A, Checa-Rodriguez C, Wiederstein JL, Baranes-Bachar K, Bartenhagen C, Hertwig F, Teper N, Nishi T, Schmitt A, Distelmaier F, Lüdecke HJ, Albrecht B, Krüger M, Schumacher B, Geiger T, Hoon DSB, Huertas P, Fischer M, Hucho T, Peifer M, Ziv Y, Reinhardt HC*,#, Wieczorek D*, Shiloh Y*: UBQLN4 represses homologous recombination and is overexpressed in aggressive tumors, Cell, 2018 Dec 21. pii: S0092-8674(18)31516-2. doi: 10.1016/j.cell.2018.11.024., * Shared last authors, # lead author contact

  • Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis A, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Büttner R and Schweiger MR: Combined targeted re-sequencing of cytosine DNA methylations and mutations for the determination of PARP1 inhibitor sensitivity. The Journal of Molecular Diagnostics, 2018 Dec 18. pii: S1525-1578(18)30247-2. doi: 10.1016/j.jmoldx.2018.10.007.
  • Torgovnick A, Schiavi A, Shaik A, Kassahun H, Maglioni S, Rea SL, Johnson TE, Reinhardt HC, Honnen S, Schumacher B, Nilsen H, Ventura N: BRCA1/BARD1 mediate apoptotic resistance but not longevity upon mitochondrial stress in C. elegans, EMBO Reports, 2018 Oct 26. pii: e45856. doi: 10.15252/embr.201845856. [Epub ahead of print]
  • Torgovnick A, Heger JM, Liaki V, Isensee J, Schmitt A, Knittel G, Riabinska A, Beleggia F, Laurien L, Leeser U, Jüngst C, Siedek F, Vogel W, Klümper N, Nolte H, Wittersheim M, Tharun L, Castiglione R, Krüger M, Schauss A, Perner S, Pasparakis M, Büttner R, Persigehl T, Hucho T, Herter-Sprie GS, Schumacher B,  Reinhardt HC: The Cdkn1aSUPER mouse as a novel tool to study p53-mediated tumor suppression. Cell Reports, 2018 Oct 23;25(4):1027-1039.e6. doi: 10.1016/j.celrep.2018.09.079.
  • Weber ANR, Gloria YC, Çınar Ö, Reinhardt HC, Pezzutto A, Wolz O-O: Oncogenic MYD88 mutations in lymphoma – novel insights and therapeutic possibilities. Cancer Immunology, Immunotherapy, 2018 Nov;67(11):1797-1807. doi: 10.1007/s00262-018-2242-9. Epub 2018 Sep 11.
  • Schmitt A, Feldmann G, Zander T, Reinhardt HC: Targeting defects in the cellular DNA damage response for the treatment of pancreatic ductal adenocarcinoma, Oncology Research and Treatment, 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.
  • Fassunke J, Muller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M,  Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML: Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications,  2018 Nov 7;9(1):4655. doi: 10.1038/s41467-018-07078-0.
  • Yang D, Denny SK, Greenside PG, Chaikovsky AC, Brady JJ, Ouadah Y, Granja JM, Jahchan NS, Lim JS, Kwok S, Kong CS, Berghoff AS, Schmitt A, Reinhardt HC, Park K-S, Preusser M, Kundaje A, Greenleaf W, Sage J, Winslow MM: Inter-tumoral heterogeneity in SCLC is influenced by the cell-type of origin. Cancer Discovery, 2018 Oct;8(10):1316-1331. doi: 10.1158/2159-8290.CD-17-0987. Epub 2018 Sep 18.
  • Meder L, Schuldt P, Thelen M, Schmitt A, Dietlein F, Klein S, Borchmann S, Wennhold K, Vlasic I, Oberbeck S, Riedel R, Florin A, Golfmann K, Schlößer HA, Odenthal M, Büttner R, Wolf J, Hallek M, Herling M, von Bergwelt-Baildon M, Reinhardt HC, Ullrich RT: Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer. Cancer Research, 2018 May 18. pii: canres.2176.2017. doi: 10.1158/0008-5472.CAN-17-2176. [Epub ahead of print]
  • Knittel G, Rehkämper T, Nieper P, Schmitt A, Flüumann R, Reinhardt HC: DNA damage pathways and B-cell lymphomagenesis. Current Opinion in Hematology, 2018 Apr 26. doi: 10.1097/MOH.0000000000000433. [Epub ahead of print]
  • Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner C-M, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst E, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M: Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nature Communications, 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
  • Welcker D, Jain M, Khurshid S, Jokic M, Höhne M, Schmitt A, Frommolt P, Niessen C, Spiro J, Persigehl T, Wittersheim M, Büttner R, Fanciulli M, Schermer B, Reinhardt HC*,#, Benzing T*,#, Hopker K#: AATF suppresses apoptosis, promotes proliferation and is critical for KRAS-driven lung cancer, Oncogene, 2018 Jan 11. doi: 10.1038/s41388-017-0054-6., * shared corresponding authors, # shared last authors
  • Schrader A, Crispatzu G, Oberbeck S, Mayer P, Pützer S, von Jan J, Vasyutina E, Warner K, Weit N, Pflug N, Braun T, Andersson E, Yadav B, Riabinska A, Maurer B, Ventura Ferreira M, Beier F, Altmueller J, Lanasa M, Herling CD, Haferlach T, Stilgenbauer S, Hopfinger G, Peifer M, Brümmendorf T, Nuernberg P, Elenitoba-Johnson K, Zha S, Hallek M, Moriggl R, Reinhardt HC, Stern M-H, Mustjoki S, Newrzela S, Frommolt P, Herling M: Integrated genetic profiles of T-PLL implicate a TCL1/ATM-centered model of aberrant, but actionable damage responses. Nature Communications, 2018 Feb 15;9(1):697. doi: 10.1038/s41467-017-02688-6.
  • Doerr F, George J, Schmitt A, Beleggia F, Rehkämper T, Vierkotten S, Walter V, Weber J-P, Thomas RK, Wittersheim M, Buttner R, Persigehl T, Reinhardt HC: Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer. Scientific Reports, 2017 Nov 14;7(1):15511. doi: 10.1038/s41598-017-15840-5.

  • Schiller J, Klein S, Engels M, Büttner R, Rybniker J, Fätkenheuer G, Scheid C, Wybranski C, Quaas A*, Reinhardt HC*, Waßermann R*: Case Report: A Cryptosporidium infection in a patient with relapsed T lymphoblastic lymphoma undergoing allogeneic stem cell transplantation. Eur J Haematol, 2017 Nov 15. doi: 10.1111/ejh.12998., * shared last authors

  • Schmitt A, Knittel G, Welcker D, Yang T-P, George J, Nowak M, Leeser U, Büttner R, Perner S, Peifer M, Reinhardt HC: ATM deficiency is associated with sensitivity to PARP1 and ATR inhibitors in lung adenocarcinoma, Cancer Research, 2017 Jun 1;77(11):3040-3056. doi: 10.1158/0008-5472.CAN-16-3398. Epub 2017 Mar 31.

  • Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Buttner R, Rauh D, Klebl BM, Thomas RK, Sos ML: Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Reports, 2017 Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082..

  • Knittel G, Rehkämper T, Korovkina D, Liedgens P, Fritz C, Torgovnick A, Al-Baldawi Y, Al-Maarri M, Cun Y, Fedorchenko O, Riabinska A, Beleggia F, Nguyen P-H, Wunderlich FT, Ortmann M, Montesinos-Rongen M, Tausch E, Stilgenbauer S, Frenzel L, Herling M, Herling C, Bahlo J, Hallek M, Peifer M, Büttner R, Persigehl T, Reinhardt HC: Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia. Nature Communications, 2017 Jul 28;8(1):153. doi: 10.1038/s41467-017-00210-6.

  • Perkhofer L, Schmitt A, Romero M, Ihle M, Hampp S, Ruess DA, Hessmann E, Russell R, Lechel A, Azoitei N, Lin Q, Liebau S, Hohwieler M, Bohnenberger H, Lesina M, Alguel H, Gieldon L, Schroeck E, Gaedcke J, Wagner M, Wiessmüller L, Sipos B, Seufferlein T, Reinhardt HC, Frappart PO, Kleger A: ATM-deficiency generates genomic instability in pancreatic ductal adenocarcinoma and sensitizes toward therapeutic DNA-damage, Cancer Research, 2017 Oct 15;77(20):5576-5590. doi: 10.1158/0008-5472.CAN-17-0634. Epub 2017 Aug 8.

  • Lohmann G, Vasyutina E, Bloehdorn J, Reinart N, Schneider JI, Babu V, Knittel G, Crispatzu G, Mayer P, Prinz C, Biersack B, Efremov DG, Chessa L, Herling CD, Stilgenbauer S, Hallek M, Schobert R, Reinhardt HC, Schumacher B, Herling M: Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia, Leukemia, 2017 May;31(5):1177-1186. doi: 10.1038/leu.2016.294. Epub 2016 Oct 24.

  • Cramer P, Eichhorst B, Reinhardt HC, Hallek M: Current strategies to create tailored and risk-adapted therapies for CLL patients. Best Pract Res Clin Haematol., 2016 Mar;29(1):111-121. doi: 10.1016/j.beha.2016.08.010. Epub 2016 Aug 12.

  • Knittel G, Liedgens P, Korovkina D, Pallasch CP, Reinhardt HC: Rewired NFκB signaling as an actionable feature of activated B cell-like DLBCL. Eur J Haematol, 2016 Aug 16. doi: 10.1111/ejh.12792. [Epub ahead of print]

  • Jokić M*, Vlašić I*, Rinneburger M*, Klümper N, Spiro J, Vogel W, Offermann A, Kümpers C, Fritz C, Schmitt A, Riabinska, Wittersheim M, Michels S, Ozretić L, Florin A, Welcker D, Akyuz MD, Nowak M, Erkel M, Wolf J, Büttner R, Schumacher B, Thomale J, Persigehl T, Maintz D, Perner S, Reinhardt HC: Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a TP53 Context-specific Manner. Molecular Cancer Research, 2016 Aug 11. pii: molcanres.0094.2016. [Epub ahead of print]

  • Thijssen R, ter Burg J, Garrick B, van Bochove GGW, Brown JR, Fernendes SM, Rodriguez M, Michot JM, Hallek M, Eichhorst BF, Reinhardt HC, Bendell J, Derks IAM, van Kampen R, Hege K, Kersten MJ, Trowe T, Filvaroff E, Eldering E, Kater A: Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia. Blood, 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

  • Herling CD, Klaumünzer M, Krings Rocha C, Altmüller J, Thiele H, Bahlo J, Kluth S, Crispatzu G, Herling M, Schiller J, Engelke A, Tausch E, Döhner H, Fischer K, Goede V, Nürnberg P, Reinhardt HC, Stilgenbauer S, Hallek M, Kreuzer K: Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy. Blood, 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25.

  • Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber ANR, Trümper L, ICGC MMML-Seq Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC: B cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B cell lymphoma in mice. Blood, 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.

  • Frenzel LP, Reinhardt HC, Pallasch CP: Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment. Oncol Res Treat, DOI:10.1159/000443820, published online Jan. 22. 2016

  • Knittel G, Liedgens P, Reinhardt HC: Targeting ATM-deficient CLL through interference with DNA repair pathways. Frontiers in Genetics, 2015 May 28, doi: 10.3389/fgene.2015.00207

  • van Vugt MATM, Reinhardt HC: Editorial: Cancer-Associated Defects in the DNA Damage Response: Drivers for Malignant Transformation and Potential Therapeutic Targets. Frontiers in Genetics, 2015 Dec 22, doi: 10.3389/fgene.2015.00355

  • George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Leenders F, Lu X, Fernandez-Cuesta L, Bosco G, Nguyen C, Berg J, Müller C, Dahmen I, Jahchan N, Yang D, Karnezis AN, Vaka D, Torres A, Menon R, Wang MS, Stuetz A, Korbel J, Wilkerson M, Hayes N, Engelmann D, Pützer B, Vlasic I, Seidel D, Pinther B, Schaub B, Becker C, Altmüller J, Yokota J, Khono T, Iwakawa R, Muley T, Peterson I, Chen Y, Soltermann A, Tischler V, Massion P, Zou Y, Wright GM, Russell P, Solomon B, Koch I, Field JK, Muscarella LA, La Torre A, Jakopovic M, Knezevic J, Heiden E, Roz L, Jovanovic D, Kontic M, Thunnissen E, Köhler J, Schuler M, Sanchez-Cespedes M, Salvesen H, Achter V, Bogus M, Schneider P, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt HC, Perner S, Heukamp LC , Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK: Comprehensive genomic profiling of small cell lung cancer. Nature, 2015 Jul 13. doi: 10.1038/nature14664 [Epub ahead of print] 

  • Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun A, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC: A synergistic interaction between Chk1- and MK2 inhibitors in KRAS-mutant cancer. Cell, Jul 2;162(1):146-159

  • Desantis A, Bruno T, Catena V, De Nicola F, Goeman F, Iezzi S, Sorino C, Gentileschi MP, Germoni S, Monteleone V, Pellegrino M, Kann M, De Meo PD, Pallocca M, Höpker K, Moretti F, Mattei E, Reinhardt HC, Floridi A, Passananti C, Benzing T, Blandino G, Fanciulli M: Che-1 modulates the decision between cell cycle arrest and apoptosis by its binding to p53. Cell Death Dis. 2015 May 21;6:e1764.

  • Boucas J, Fritz C, Schmitt A, Riabinska A, Thelen L, Peifer M, Leeser U, Nuernberg P, Altmueller J, Gaestel M, Dieterich C, Reinhardt HC: Label-Free Protein-RNA Interactome Analysis Identifies Khsrp Signaling Downstream of the p38/Mk2 Kinase Complex as a Critical Modulator of Cell Cycle Progression. PLOS ONE. 2015 May 20;10(5):e0125745.

  • Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC: A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC. Cancer Discovery, 2014 May;4(5):592-605.

  • Huelsemann M, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker H, Theurich S, von Bergwelt-Baildon M, Pallasch C, Zahedi R, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel L: Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 2015 Apr;29(4):981-4

  • Dietlein F, Reinhardt HC: Molecular Pathways: Exploiting cancer-specific defects in homology-mediated DNA repair for personalized therapy. Clin Canc Res, 2014 Dec 1;20(23):5882-7

  • Dietlein F, Thelen L, Reinhardt HC: Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. TRENDS in Genetics, 2014 Jul 10. 2014 Aug;30(8):326-39.

  • Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich R, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK: Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discovery, Published Online First December 3, 2013; doi:10.1158/2159-8290.

  • Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Jacks T, Yaffe MB: A novel Cre-versible approach identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Reports, 2013 Nov 13. doi:pii: S2211-1247(13)00609-8. 10.1016/j.celrep.2013.10.025.

  • Franke M, Reinhardt HC, v. Bergwelt-Baildon M, Bangard C: Massive air embolism following lung biopsy. Circulation, 2014 Mar 4;129(9):1046-7.

  • Reinhardt HC, Yaffe MB. Phosphoserine/threonine binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol. 2013 Sep;14(9):563-80.

  • Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas JM, Chen S, Reinhardt HC: Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med, 2013 Jun 12;5(189):189ra78. doi: 10.1126/scitranslmed.3005814.

  • Höpker K, Reinhardt HC: p53-regulating pathways as targets for personalized cancer therapy. Dtsch Med Wochenschr, 2013 Jan;138(3):82-6. doi: 10.1055/s-0032-1327380.

  • Habbig S, Bartram MP, Sägmüller JG, Franke M, Müller RU, Schwarz R, Hoehne M, Bergmann C, Reinhardt HC, Burst V, Benzing T, Schermer B: The ciliopathy disease protein NPHP9 controls nuclear delivery and activation of the oncogenic transcriptional regulator TAZ, Hum Mol Genet, 2012 Dec 15;21(26):5528-38.

  • Höpker K, Hagmann H, Khurshid S, Chen S, Schermer B, Benzing T, Reinhardt HC: Putting the brakes on p53-driven apoptosis. Cell Cycle, 2012 Sep 14;11(22).

  • Boucas J, Höpker K, Chen S, Herter-Sprie GS, Jokic M, Riabinska A, Reinhardt HC: Posttranscriptional regulation of gene expression – adding another layer of complexity to the DNA damage response. Frontiers in Genetics, 2012;3:159.

  • Höpker K, Hagmann H, Khurshid S, Chen S, Hasskamp P, Seeger-Nukpezah T, Schilberg K, Heukamp L, Lamkemeyer T, Sos M, Thomas R, Lowery D, Fischer M, Roels F, Liebau MC, Resch U, Kisner T, Röther F, Bartram MP, Müller RU, Fabretti F, Kurschat P, Schumacher B, Medema R, Yaffe MB, Schermer B, Reinhardt HC*, Benzing T*: AATF/Che1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO J, 2012 Oct 17;31(20):3961-75. *equal contribution

  • Reinhardt HC, Schumacher B: The p53 network: Cellular and systemic DNA damage responses in aging and cancer, TRENDS in Genetics, 2012 Mar;28(3):128-36.

  • Höhne M, Lorscheider J, Von Bardeleben A, Dufner M, Scharf MA, Gödel M, Helmstädter M, Schurek EM, Zank S, Gerke P, Kurschat C, Sivritas SH, Neumann-Haefelin E, Huber TB, Reinhardt HC, Schermer B, Fischbach KF, Benzing T: The BAR domain protein PICK1 regulates cell recognition and morphogenesis by interacting with Neph proteins. Mol Cell Biol. 2011 Aug;31(16):3241-51.

  • Herter-Sprie GS, Chen S, Höpker K, Reinhardt HC. Synthetic lethality as a new concept for the treatment of cancer. Dtsch Med Wochenschr, 2011 Jul;136(30):1526-30. Epub 2011 Jul 25.

  • Chen S, Herter-Sprie GS, Höpker K, Reinhardt HC. The p38/MK2 pathway as a novel target for chemosensitizing therapy. Dtsch Ztsch Klin Forsch, 15 03/04 2011

  • Habbig S, Bartram MP, Müller RU, Schwarz R, Andriopoulos N, Chen S, Sägmüller JG, Hoehne M, Burst V, Liebau MC, Reinhardt HC, Benzing T, and Schermer B: NPHP4, a cilia-associated protein, negatively regulates the Hippo pathway. J Cell Biol. 2011 May 16;193(4):633-42.

  • Reinhardt HC, Morandell S, Yaffe MB. Is post-transcriptional stabilization, splicing and translation of selective mRNAs a key to the DNA damage response? Cell Cycle, 2011 Jan 1;10(1):23-7.

  • Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt M, Wang X, Linding R, Ong SE, Weaver D, Carr SA, Yaffe MB. DNA Damage activates A Spatially Distinct Late Cytoplasmic Cell Cycle Checkpoint Network Controlled by MK2-mediated RNA Stabilization. Mol Cell, 2010, 40;1, 34-49, 2010 Oct 8

  • van Vugt M, Gardino A, Linding R, Ostheimer G, Reinhardt HC, Ong S-E, Tan C, Maio H, Keezer S, Li R, Pawson T, Lewis T, Carr S, Smerdon S, Brummelkamp T, and Yaffe MB: A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1 and Chk2 to Inactivate the G2/M DNA Damage Checkpoint. PLOS Biology, 2010, Jan 26;8(1)

  • Janes KA*, Reinhardt HC*, and Yaffe MB: The Apoptotic Signaling Network Dynamically Interprets the Outputs of Individual Signaling Pathways in an Early Analog and Late Digital Manner. Proceedings of the Uehara Memorial Foundation, in press, *equal contribution

  • Reinhardt HC, Jiang H, Hemann MT and Yaffe MB: Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle, 2009 Oct 1;8(19):3112-9.

  • Jiang H*, Reinhardt HC*, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT: The ATM-Chk2 Signaling Network Controls 
Alternative Cell Fates after Chemotherapy Based on a p53 Binary
Switch. Genes Dev. 2009 Aug 15;23(16):1895-909. *equal contribution

  • Reinhardt HC, and Yaffe MB: Kinases that Control the Cell Cycle in Response to DNA Damage: Chk1, Chk2, and MK2. Curr. Opin. Cell. Biol., 2009 Apr;21(2):245-55.

  • Janes KA*, Reinhardt HC*, and Yaffe MB: Cytokine-induced signaling networks prioritize dynamic range over signal strength. Cell, 2008 Oct 17;135(2):343-54.*equal contribution

  • Duning K, Schurek EM, Schlüter M, Bayer M, Reinhardt HC, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, Huber TB, Bachmann S, Kremerskothen J, Weide T, Pavenstädt H.: KIBRA modulates directional migration of podocytes. J Am Soc Nephrol. 2008 Oct;19(10):1891-903.

  • Wilker EW, van Vugt MA, Artim SA, Huang PH, Petersen CP, Reinhardt HC, Feng Y, Sharp PA, Sonenberg N, White FM, Yaffe MB.: 14-3-3sigma controls mitotic translation to facilitate cytokinesis. Nature. 2007 Mar 15;446(7133)

  • Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB: p53 deficient cells rely on ATM and ATR-mediated checkpoint signaling through the p38 MAPK/MK2 pathway for survival after DNA damage. Cancer Cell, 2007 Feb;11(2):175-89.

  • Huber TB, Schermer B, Muller RU, Hohne M, Bartram M, Calixto A, Hagmann H, Reinhardt HC, Koos F, Kunzelmann K, Shirokova E, Krautwurst D, Harteneck C, Simons M, Pavenstadt H, Kerjaschki D, Thiele C, Walz G, Chalfie M, Benzing T.: Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17079-17086.

  • Pache G, Schafer C, Wiesemann S, Springer E, Liebau M, Reinhardt HC, August C, Pavenstadt H, Bek M: Up-regulation of Id-1 via BMP-2 Receptors Induces Re-active Oxygen Species in Podocytes.Am J Physiol Renal Physiol. 2006 Apr 18;

  • Bek MJ, Reinhardt HC, Fischer KG, Hirsch JR, Hupfer C, Dayal E, Pavenstädt H. Upregulation of early growth response gene-1 via the CXCR3 receptor induces reactive oxygen species and the inhibits Na+/K+-ATPase activity in an immortalized human proximal tubule cell line. J Immunol. 2003 Jan 15; 170(2)

  • Huber TB*, Reinhardt HC*, Exner M, Burger JA, Kerjaschki D, Saleem MA, Pavenstadt H.: Expression of functional CCR and CXCR chemokine receptors in podocytes. J Immunol 2002 Jun 15; 168(12): 6244-52 *equal contribution